‘Mistakes’ Can Be Advantageous

1
465

A ‘Mistake’ May Have Made a More Efficacious COVID-19 Vaccine

Health Editor’s Note: Surprising information on the COVID-19 vaccine front. AstraZeneca is investigating why one-half dose of the primer vaccine seems to have raised the efficacy of the vaccine. While the half-dose was an error, this dose seems to have been as effective as two full doses and the hypothesis is that the lower dose ‘primed’ the immune system and created a super immune reaction.  Sometimes mistakes happen for a reason as we move toward an effective, safe vaccine against COVID-19…..Carol

 

 

Biography
Carol graduated from Riverside White Cross School of Nursing in Columbus, Ohio and received her diploma as a registered nurse. She attended Bowling Green State University where she received a Bachelor of Arts Degree in History and Literature. She attended the University of Toledo, College of Nursing, and received a Master’s of Nursing Science Degree as an Educator.

She has traveled extensively, is a photographer, and writes on medical issues. Carol has three children RJ, Katherine, and Stephen – one daughter-in-law; Katie – two granddaughters; Isabella Marianna and Zoe Olivia – and one grandson, Alexander Paul. She also shares her life with husband Gordon Duff, many cats, and two rescue pups.

Carol’s Archives 2009-2013
ATTENTION READERS
Due to the nature of independent content, VT cannot guarantee content validity.
We ask you to Read Our Content Policy so a clear comprehension of VT's independent non-censored media is understood and given its proper place in the world of news, opinion and media.

All content is owned by author exclusively. Expressed opinions are NOT necessarily the views of VT, other authors, affiliates, advertisers, sponsors, partners or technicians. Some content may be satirical in nature. All images within are full responsibility of author and NOT VT.

About VT - Read Full Policy Notice - Comment Policy

1 COMMENT

  1. In the low-dose trial, none of the participants were over 55 years old and the efficacy was 90%. In the full-dose trial the efficacy was 62%. Could this suggest that the vaccine is less effective in the older population that is said to be at an increased risk if they contract Covid-19?
    Since only one of the two doses in the low-dose trial was a half-dose, perhaps it would be informative to test what happens if both doses are half-doses. Also, if the first dose as a half-dose was better than the first dose as a full-dose could a first dose at a quarter-dose produce better results than having the first dose as a half-dose?